Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.36 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15070654 | 0.93 | SLC28A1 (0.38) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17861819 | 0.93 | SLC28A1 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL15070470 | 0.93 | SLC28A1 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17357658 | 0.91 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18417739 | 0.89 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL15070411 | 0.89 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17861838 | 0.89 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17861871 | 0.89 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL15070676 | 0.89 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL15070537 | 0.89 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-9603863-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | SLC28A1 32/4885SLC28A2 46/4885SLC29A1 14/4885 |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | SLC28A1 32/4885SLC28A2 46/4885SLC29A1 14/4885 |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | SLC28A1 16/4885SLC28A2 20/4885SLC29A1 5/4885 |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | SLC28A1 16/4885SLC28A2 20/4885SLC29A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.